1 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001589)
|
2 |
US patent application no. 7,175,854, Pharmaceutical preparation comprising an active dispersed on a matrix.
|
3 |
Effect of the leukotriene LTD4/LTE4 antagonist, SR 2640, in ulcerative colitis: an open clinical study. Prostaglandins Leukot Essent Fatty Acids. 1991 Mar;42(3):181-4.
|
4 |
Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance. Eur J Med Res. 1997 Apr 21;2(4):159-64.
|
5 |
Antiallergy activity of Sch 37224, a new inhibitor of leukotriene formation. J Pharmacol Exp Ther. 1988 Dec;247(3):997-1003.
|
6 |
WF11605, an antagonist of leukotriene B4 produced by a fungus. II. Structure determination. J Antibiot (Tokyo). 1992 May;45(5):704-8.
|
7 |
Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig. Pulm Pharmacol. 1991;4(3):177-89.
|
8 |
Effect of SMP-028 on steroidogenesis in rats; mechanism of toxicological events on endocrine organs of rats. Toxicol In Vitro. 2014 Apr;28(3):397-402.
|
9 |
Effects of NZ-107 on tracheal responses to adenosine in the guinea pig. Jpn J Pharmacol. 1991 May;56(1):79-84.
|
10 |
An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010 February; 10(1): 60-66.
|
11 |
The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum. 1996 Mar;39(3):515-21.
|
12 |
In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther. 1987 Nov;243(2):548-56.
|
|
|
|
|
|
|